CAN attended the British Nuclear Medicine Society (BNMS) Autumn Meeting 2025

On 30th September, our our Scientific Officer, Amin Choudhury and Business Development Manager, Paul Adlem, attended the British Nuclear Medicine Society (BNMS) Autumn Meeting 2025 at The Oval in London.

The event provided them with the opportunity to build valuable connections with industry leaders who are driving innovation in nuclear medicine and radiopharmaceuticals. A big thank you to Scitech, Siemens, George Hunter from Lablogic, Life Molecular Imaging, and the teams at Life Couriers and Nuvia Tech for the insightful discussions.

There is a growing momentum around targeted alpha therapy (TAT), with exciting developments occurring across the UK’s radiopharmacy sites. It’s encouraging to see the industry aligning on quality control standards, transportation solutions, and the manufacturing capabilities needed to deliver these promising therapies to patients.

The key takeaways from this event include the importance of collaboration as we navigate the evolving landscape and the UK’s positioning as a significant player in the development of next-generation radiopharmaceutical infrastructure. 💡

We look forward to the Spring 2026 meeting in Manchester!